Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
15.5M
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
518K
-
Shares change
-
+518K
-
Total reported value, excl. options
-
$1.44M
-
Value change
-
+$1.44M
-
Number of buys
-
7
-
Price
-
$2.78
Significant Holders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (ACST) as of Q3 2023
9 filings reported holding ACST - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (ACST) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 518K shares
of 15.5M outstanding shares and own 3.34% of the company stock.
Largest 10 shareholders include BANK OF AMERICA CORP /DE/ (495K shares), TD PRIVATE CLIENT WEALTH LLC (40.1K shares), Coastal Bridge Advisors, LLC (10K shares), UBS Group AG (4.71K shares), JPMORGAN CHASE & CO (3.36K shares), NATIONAL BANK OF CANADA /FI/ (2.9K shares), MORGAN STANLEY (1.88K shares), Federation des caisses Desjardins du Quebec (28 shares), Impact Partnership Wealth, LLC (10 shares), and Royal Bank of Canada (584 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.